Immuneering Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Immuneering Corp
IMRX Stock  USD 4.63  0.24  4.93%   
Immuneering Corp's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Immuneering Corp's valuation are provided below:
Gross Profit
158.8 K
Market Capitalization
314.5 M
Enterprise Value Revenue
191.9 K
Revenue
455
Earnings Share
(1.79)
We have found one hundred twenty available fundamental trends for Immuneering Corp, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Immuneering Corp regular market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 72.1 M in 2026. Enterprise Value is likely to drop to about 37.1 M in 2026

Immuneering Corp Total Revenue

0.0

Check Immuneering Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immuneering Corp's main balance sheet or income statement drivers, such as Net Interest Income of 3.1 M, Interest Income of 3.1 M or Depreciation And Amortization of 233 K, as well as many indicators such as Price To Sales Ratio of 382, Dividend Yield of 0.0 or PTB Ratio of 1.51. Immuneering financial statements analysis is a perfect complement when working with Immuneering Corp Valuation or Volatility modules.
  
Build AI portfolio with Immuneering Stock
Check out the analysis of Immuneering Corp Correlation against competitors.
For more information on how to buy Immuneering Stock please use our How to Invest in Immuneering Corp guide.

Immuneering Corp Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets91.1 M60.6 M45.6 M
Slightly volatile
Short and Long Term Debt Total4.8 M3.7 M11.4 M
Slightly volatile
Other Current Liabilities3.7 M6 M1.9 M
Slightly volatile
Total Current Liabilities5.8 M8.6 M3 M
Slightly volatile
Property Plant And Equipment Net4.2 M5.5 M1.9 M
Slightly volatile
Accounts Payable1.9 M2.3 M1 M
Slightly volatile
Cash53.9 M41.6 M30.2 M
Slightly volatile
Non Current Assets Total10.1 M15.1 M4.8 M
Slightly volatile
Cash And Short Term Investments78.4 M41.6 M39.5 M
Slightly volatile
Common Stock Total Equity17.2 K30.4 K12.2 K
Slightly volatile
Common Stock Shares Outstanding25.3 M34.5 M18.8 M
Slightly volatile
Liabilities And Stockholders Equity91.1 M60.6 M45.6 M
Slightly volatile
Non Current Liabilities Total3.3 M3.4 M16.7 M
Slightly volatile
Other Current Assets2.4 M4 M1.2 M
Slightly volatile
Other Stockholder Equity176 M305.5 M85.9 M
Slightly volatile
Total Liabilities17.1 M10.2 M20.1 M
Pretty Stable
Property Plant And Equipment Gross7.1 M6.8 M1.7 M
Slightly volatile
Total Current Assets81 M45.5 M40.9 M
Slightly volatile
Capital Stock22.5 K35.7 K13.3 K
Slightly volatile
Net Working Capital35.1 M36.9 M35.5 M
Slightly volatile
Common Stock22.5 K35.7 K13.3 K
Slightly volatile
Property Plant Equipment794.6 K1.6 M489.2 K
Slightly volatile
Other Assets0.860.959 K
Pretty Stable
Short Term Debt300.9 K389.2 K165.9 K
Slightly volatile
Capital Surpluse239.2 M252.6 M219.6 M
Slightly volatile
Intangible Assets315.6 K315.4 K414 K
Slightly volatile
Current Deferred Revenue4.1 M4.7 M5.1 M
Slightly volatile

Immuneering Corp Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income3.1 M3 M816.4 K
Slightly volatile
Depreciation And Amortization233 K442.8 K124.1 K
Slightly volatile
Interest Expense1.2 M1.2 M540.7 K
Slightly volatile
Selling General Administrative11.5 M18.5 M6.9 M
Slightly volatile
Other Operating Expenses43.7 M73.7 M25.3 M
Slightly volatile
Research Development31.5 M55.2 M17.5 M
Slightly volatile
Cost Of Revenue705.6 K642.1 K1 M
Slightly volatile
Total Operating Expenses43 M73.7 M24.3 M
Slightly volatile
Reconciled Depreciation421.1 K442.8 K195.5 K
Slightly volatile
Selling And Marketing Expenses409.5 K460.7 K502.8 K
Slightly volatile

Immuneering Corp Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Change To Inventory14 K15.8 K17.2 K
Slightly volatile
Net Borrowings3.1 M3.4 M3.8 M
Slightly volatile
Stock Based Compensation7.9 M7.5 M2.4 M
Slightly volatile
Begin Period Cash Flow47.5 M68.3 M22.6 M
Slightly volatile
Other Cashflows From Financing Activities911.5 K959.5 K11.7 M
Slightly volatile
Depreciation328.2 K442.8 K160.2 K
Slightly volatile
Capital Expenditures92.7 K97.6 K98.8 K
Slightly volatile
Issuance Of Capital Stock3.6 M3.8 M22.7 M
Pretty Stable
Total Cash From Financing Activities4.5 M4.8 M23.4 M
Very volatile
End Period Cash Flow53.9 M41.6 M30.2 M
Slightly volatile
Change To Netincome2.6 M4.7 M3 M
Slightly volatile
Sale Purchase Of Stock16.2 K17.1 K101.8 M
Slightly volatile
Change Receivables205.3 K210.3 K263.1 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio382363206
Slightly volatile
Days Sales Outstanding15.6216.4435.0746
Slightly volatile
Average Payables1.4 M2.4 M1.3 M
Slightly volatile
Stock Based Compensation To Revenue0.440.780.4862
Slightly volatile
Capex To Depreciation0.240.250.8838
Slightly volatile
EV To Sales113171134
Slightly volatile
Payables Turnover0.05480.05762.554
Slightly volatile
Sales General And Administrative To Revenue46.5344.3215.1768
Slightly volatile
Research And Ddevelopement To Revenue10810335.0544
Slightly volatile
Capex To Revenue2.212.110.6769
Slightly volatile
Cash Per Share1.031.091.7031
Slightly volatile
Days Payables Outstanding6.9 K6.6 K2.2 K
Slightly volatile
Income Quality0.670.810.6888
Slightly volatile
Intangibles To Total Assets0.06060.120.0562
Slightly volatile
Net Debt To EBITDA0.550.581.5811
Slightly volatile
Current Ratio5.766.0721.4145
Slightly volatile
Receivables Turnover24.1222.9713.4226
Slightly volatile
Capex Per Share0.00240.00250.0041
Slightly volatile
Average Receivables6.8 K7.1 K100.4 K
Slightly volatile
Revenue Per Share0.01310.01380.102
Slightly volatile
Interest Debt Per Share0.10.120.0711
Slightly volatile
Debt To Assets0.07460.07110.0305
Slightly volatile
Operating Cycle15.6216.4435.0746
Slightly volatile
Days Of Payables Outstanding6.9 K6.6 K2.2 K
Slightly volatile
Ebt Per Ebit1.111.11.1359
Slightly volatile
Effective Tax Rate0.00560.00820.0061
Slightly volatile
Quick Ratio5.766.0721.4145
Slightly volatile
Net Income Per E B T0.80.90.9786
Slightly volatile
Cash Ratio5.265.5419.688
Slightly volatile
Days Of Sales Outstanding15.6216.4435.0746
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.810.90.9875
Slightly volatile
Fixed Asset Turnover0.05990.063132.2492
Slightly volatile
Debt Ratio0.07460.07110.0305
Slightly volatile
Price Sales Ratio382363206
Slightly volatile
Asset Turnover0.00280.0030.0852
Slightly volatile
Gross Profit Margin0.350.450.4014
Slightly volatile

Immuneering Corp Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap72.1 M75.9 M211.2 M
Slightly volatile
Enterprise Value37.1 M39.1 M183.6 M
Slightly volatile

Immuneering Fundamental Market Drivers

Immuneering Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Immuneering Corp Financial Statements

Immuneering Corp investors use historical fundamental indicators, such as Immuneering Corp's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immuneering Corp. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue4.7 M4.1 M
Cost Of Revenue642.1 K705.6 K
Stock Based Compensation To Revenue 0.78  0.44 
Sales General And Administrative To Revenue 44.32  46.53 
Research And Ddevelopement To Revenue 102.98  108.13 
Capex To Revenue 2.11  2.21 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(187.75)(178.36)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CCitigroup
SSentinelOne

Additional Tools for Immuneering Stock Analysis

When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY